sodium iodide (131I) 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
radiopharmaceuticals, iodine-contained 5038 7790-26-3

Description:

MoleculeDescription

Synonyms:

  • sodium iodide (131I)
  • sodium iodide I-131
  • iodotope
  • sodium iodide I 131
  • Molecular weight: 153.90
  • Formula: INa
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
May 2, 1957 FDA BRACCO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Parathyroid tumour benign 183.40 65.06 25 568 911 90626943
Hypothyroidism 156.35 65.06 41 552 53086 90574768
Endocrine ophthalmopathy 139.42 65.06 20 573 1054 90626800
Sialoadenitis 103.66 65.06 17 576 2165 90625689
Dacryostenosis acquired 97.03 65.06 14 579 765 90627089
Acute leukaemia 83.55 65.06 13 580 1183 90626671
Abortion spontaneous 78.05 65.06 24 569 54032 90573822

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypothyroidism 88.59 82.76 22 182 32062 42589069
Endocrine ophthalmopathy 82.79 82.76 10 194 190 42620941

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypothyroidism 363.16 54.72 87 708 72812 110515692
Parathyroid tumour benign 227.11 54.72 31 764 1034 110587470
Endocrine ophthalmopathy 219.24 54.72 31 764 1342 110587162
Dacryostenosis acquired 146.47 54.72 20 775 664 110587840
Acute leukaemia 90.59 54.72 15 780 1834 110586670
Hyperthyroidism 76.16 54.72 21 774 29240 110559264
Treatment failure 65.10 54.72 34 761 277200 110311304
Radiation thyroiditis 65.08 54.72 6 789 0 110588504
Lacrimation increased 61.50 54.72 18 777 30932 110557572
Thyrotoxic crisis 55.33 54.72 10 785 2030 110586474
Thyroid cancer 55.26 54.72 12 783 6202 110582302

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V09FX03 VARIOUS
DIAGNOSTIC RADIOPHARMACEUTICALS
THYROID
Various thyroid diagnostic radiopharmaceuticals
ATC V10XA01 VARIOUS
THERAPEUTIC RADIOPHARMACEUTICALS
OTHER THERAPEUTIC RADIOPHARMACEUTICALS
Iodine (131I) compounds
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

V10XA Iodine (131I) compounds 1 drug
iobenguane (131I)

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hyperthyroidism indication 34486009 DOID:7998
Carcinoma of thyroid indication 448216007




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D02259 KEGG_DRUG
4017585 VUID
N0000145966 NUI
4017585 VANDF
C0304982 UMLSCUI
CHEBI:749371 CHEBI
CHEMBL1201084 ChEMBL_ID
71368 PUBCHEM_CID
91535 RXNORM
1798 MMSL
20994 MMSL
83206 MMSL
d00661 MMSL
007948 NDDF
111160004 SNOMEDCT_US
783854008 SNOMEDCT_US
279 INN_ID
29VCO8ACHH UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
I 131 Mini HUMAN PRESCRIPTION DRUG LABEL 1 51808-119 CAPSULE 500 mCi ORAL Unapproved drug other 6 sections
Sodium Iodide I 131 Diagnostic HUMAN PRESCRIPTION DRUG LABEL 1 65174-461 CAPSULE 100 mCi ORAL NDA 23 sections
HICON Human Prescription Drug Label 1 65174-880 SOLUTION 1000 mCi ORAL NDA 25 sections